Codexis (CDXS) announced the appointment of Cynthia Collins to the Company’s Board of Directors. She currently serves as Executive Chair and interim CEO of Nutcracker Therapeutics, a contract, research, development and manufacturing organization with a next generation RNA precision manufacturing platform
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDXS:
- Codexis Appoints Cynthia Collins to Board of Directors
- Investors should buy Codexis following contract news, says Craig-Hallum
- Codexis announces first revenue-generating contract for ECO Synthesis services
- Codexis Earnings Call: Growth Prospects and Challenges
- Codexis Reports 2024 Results, Eyes Growth in 2025